A recent meta-analysis illustrated the association between Gal-3 levels and a high risk of long-term adverse outcomes in patients with HFpEF, including all-cause mortality (HR: 1.55; 95% CI: 1.27–1.87; p = 0.138, I2 = 42%), the composite of all-cause death and HF hospitalization (HR: 1.50; 95% CI: 1.30–1.74; p = 0.001, I2 = 61%) and CV death and HF hospitalizations (HR: 1.71; 95% CI: 1.51–1.94; p = 0.036, I2 = 58%) [24]. This evidence concerns the gene LGALS3 and hydrops fetalis.